Cecilia Brown

Blood Cancers Today

Allogeneic hematopoietic stem cell transplantation (HSCT) &ldquo;remains a curative option&rdquo; for certain patients with large B-cell lymphoma (LBCL) who relapse after chimeric antigen receptor (CAR) T-cell therapy, according to research presented at the 64th American Society of Hematology Annual Meeting and Exposition.The researchers conducted a retrospective study including all patients who underwent allogeneic HSCT or received CAR T-cell therapy at a single center in France between February 2010 and January 2022. They analyzed data from 95 patients with relapsed/refractory LBCL, 35 of whom underwent allogeneic HSCT and 56 of whom received CAR-T therapy. Patients who underwent transplant had a median of three prior lines of therapy, while those receiving CAR-T had a median of two prior lines of therapy.The median patient age was 56 years old in patients undergoing transplant, while it was 58 years old in patients receiving CAR-T therapy. A significantly greater proportion of patients receiving CAR-T therapy had primary refractory disease (71.4%) than those who underwent allogeneic HSCT (38.4%).The two-year overall survival rate was 69% in patients who underwent allogeneic HSCT, while it was 67% for those receiving CAR-T. The two-year progression-free survival rate was 66% in patients who underwent allogeneic HSCT, while it was 43% for those receiving CAR-T.At a median follow-up of 23.2 months, half of the patients receiving CAR-T had disease progression/relapse, with five patients undergoing allogeneic HSCT after CAR-T failure. Of those five patients, one had a partial response at the time of conditioning and four others had complete response. At a median follow-up of 14 months, four of those patients were still in response, with one having an early relapse.&ldquo;Our results confirm efficacy and safety of CAR-T in [relapsed/refractory] LBCL, with durable complete responses in about 40% of patients in the third-line setting,&rdquo; the study&rsquo;s authors concluded. &ldquo;However, early failures after infusion require prompt diagnosis and management because they portend a very dismal prognosis. In this context, our data show that [allogeneic HSCT] remains a curative option for selected LBCL patients relapsing after CAR T-cell therapy with manageable toxicity.&rdquo;ReferenceRoch&eacute; P, Brisou G, Furst S, et al. Allogeneic transplant as a curative option for relapsed/refractory large B-cell lymphoma in the era of CAR T-cell therapy: a monocentric retrospective study. Abstract #3445. Presented at the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Louisiana.

Allogeneic HSCT Still a 'Curative Option' After CAR-T in LBCL

The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.

Aggressive B-Cell Lymphoma

Allogeneic HSCT “remains a curative option” for certain patients with large B-cell lymphoma who relapse after CAR T-cell therapy.

Allogeneic HSCT a 'Curative Option' After CAR-T in LBCL

Editorial Board

About Us

Terms of Use

Advertising

Privacy Policy

Editorial Policy

MashupMD

GU Oncology Now

Cancer Nursing Today

Urban Health Today

DocWire News

eNewsletters

Calendar of Events

Contact Us

Contribute

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Leukemia

Hodgkin Lymphoma

Indolent B-Cell Lymphoma

Mantle Cell Lymphoma

T-Cell Lymphoma

Lymphoma

Myelofibrosis

Polycythemia Vera

Myeloma

Transplantation & Cellular Therapy

The HemOnc Pulse

Meeting News

The HemOnc Pulse Live

Video Insights

In Print

Subscribe